Summit Therapeutics PLC  

(Public, LON:SUMM)   Watch this stock  
Find more results for SUMM
130.00
-5.00 (-3.70%)
Jul 7 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 130.00 - 136.00
52 week 100.00 - 188.00
Open 135.00
Vol / Avg. 55,431.00/58,465.00
Mkt cap 80.56M*
P/E     -
Div/yield     -
EPS -0.28*
Shares 61.23M
Beta     -
Inst. own     -
*GBP
May 6, 2015
Full Year 2014 Summit Therapeutics PLC Earnings Call - Webcast
May 6, 2015
Full Year 2014 Summit Therapeutics PLC Earnings Release
  

Key stats and ratios

Q2 (Apr '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -47.63% -85.14%
Return on average equity -55.29% -115.20%
Employees 23 -
CDP Score - -

Address

85B Park Drive
ABINGDON, OX14 4RY
United Kingdom - Map
+44-1235-443939 (Phone)
+44-1235-436237 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Summit Therapeutics plc, formerly Summit Corporation plc, is a United Kingdom-based drug discovery and development company. The Company is engaged in developing drug candidates to treat Duchenne Muscular Dystrophy (DMD), a genetic disease, and Clostridium difficile Infection (CDI), an infectious disease. The Company is developing a pipeline of utrophin modulators that comprise its lead candidate SMT C1100 and next generation modulators that are at an earlier stage of development. SMT C1100 is in a Phase 1b clinical trial. The Company is developing SMT19969 as an antibiotic that is a potential treatment for initial CDI that could significantly reduce rates of recurrent disease. SMT19969 completed a Phase 1 clinical trial in healthy volunteers with the results showing it to be safe and well tolerated at all doses tested, including the expected therapeutic dose. The Company’s subsidiaries include Summit (Oxford) Limited and Summit (Wales) Limited.

Officers and directors

Glyn Edwards Chief Executive Officer, Executive Director
Age: 58
Erik Ostrowski Chief Financial Officer
Age: 41
Frank Murdoch Armstrong Non-Executive Chairman of the Board
Age: 58
Valerie L. Andrews Non-Executive Director
Age: 55
Stephen J. Davies Non-Executive Director
Age: 64
Barry J. Price Ph.D. Non-Executive Director
Age: 70
David M. Wurzer CPA Non-Executive Director
Age: 56